On Oct 15, major Wall Street analysts update their ratings for $Nurix Therapeutics (NRIX.US)$, with price targets ranging from $29 to $35.
J.P. Morgan analyst Eric Joseph maintains with a buy rating, and adjusts the target price from $34 to $31.
Barclays analyst Peter Lawson maintains with a buy rating, and maintains the target price at $31.
Wells Fargo analyst Derek Archila maintains with a buy rating, and maintains the target price at $32.
Needham analyst Gil Blum maintains with a buy rating, and maintains the target price at $29.
Stifel analyst Stephen Willey maintains with a buy rating, and adjusts the target price from $30 to $34.
Furthermore, according to the comprehensive report, the opinions of $Nurix Therapeutics (NRIX.US)$'s main analysts recently are as follows:
Nurix Therapeutics is centered on targeted protein modulation in cancer treatment. Its principal BTK degrader is designed to more effectively target a wide array of BTK mutations compared to inhibitors and shows favorable comparisons against a limited field of comp degraders. Initial Phase 1a results appear promising, suggesting potential combined peak adjusted sales of $2.8 billion for the three initial indications.
Here are the latest investment ratings and price targets for $Nurix Therapeutics (NRIX.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
